HomeAI · summaries
Storia in 6 fonti
FDA approves Pasatru to reduce lesions, flare-ups in fibrodysplasia ossificans progressiva
The FDA approved a novel therapy for reducing the formation of heterotopic ossification lesions and flare-ups for adults with fibrodysplasia ossificans progressiva, according to an industry press release.Garetosmab-grts (Pasatru, Regeneron) is a monoclonal antibody administered through IV infusion. According to Regeneron, the therapy is the first approved by the FDA for reducing new heterotopic
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
medpagetoday.com
FDA Approves Activin Signaling Inhibitor for Bone Disorder
Ultra-rare fibrodysplasia ossificans progressiva now has its second approved drug
- ·
fiercepharma.com
Regeneron's Pasatru scores FDA approval in ultrarare bone lesions disorder
After more than 10 years in development, Regeneron secured a landmark approval for its monoclonal antibody garetosmab, now commercially known as Pasatru. | Regeneron's Pasatru has…
